Welcome to our dedicated page for Senestech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SenesTech, Inc. (NASDAQ: SNES) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. SenesTech is a biotechnology company focused on fertility control for managing rodent populations, and its filings offer detailed information on its operations, financing activities, and governance.
Key documents available through EDGAR and summarized with AI-powered insights include Form 10-K annual reports, which describe the business, risk factors, and strategy around products such as ContraPest® and the Evolve rodent birth control line, and Form 10-Q quarterly reports, which update investors on revenues, gross margins, operating expenses, and cash position. These periodic reports help readers understand how SenesTech’s fertility control products and multi-channel distribution efforts are reflected in its financial statements.
SenesTech also files numerous Form 8-K current reports documenting material events. Recent 8-K filings describe warrant inducement agreements and related financings, at-the-market offering prospectus supplements, the appointment and compensation of an interim chief operating officer, board changes, and the release of quarterly financial results. These filings provide structured detail on capital raises, equity-linked securities, and key management decisions.
Through this page, users can also review registration statements and prospectus supplements referenced in 8-Ks, which outline at-the-market equity programs and additional registered shares. Stock Titan’s tools surface new filings in real time and apply AI-generated summaries to highlight the main points of lengthy documents, helping investors quickly locate information on SenesTech’s financial condition, equity offerings, and significant corporate events without reading every page manually.
SenesTech has announced an At The Market (ATM) offering of up to $843,069 of common stock through H.C. Wainwright & Co. The offering will be conducted on the Nasdaq Capital Market (SNES) at prevailing market prices, with Wainwright receiving a 3.0% commission on gross sales.
Key details of the offering:
- Last reported stock price: $3.96 per share (June 20, 2025)
- Current market cap (non-affiliate): $8.56 million based on 2,015,291 shares
- Previous sales under Form S-3: $2,011,926.24 in past 12 months
The company specializes in fertility control products for pest management, with two main product lines: ContraPest and Evolve. Recent developments include the January 2024 launch of Evolve Rat and May 2024 launch of Evolve Mouse, both classified as minimum risk pesticides. ContraPest is registered in all 50 states, while Evolve Rat is authorized in 48 states and Evolve Mouse in 36 states.
SenesTech has filed a prospectus for the resale of up to 1,517,608 shares of common stock, comprising 1,498,872 Inducement Shares (exercise price $2.90) and 18,736 Placement Agent Shares (exercise price $3.625). The shares are issuable upon exercise of outstanding warrants.
Key highlights:
- Trading on Nasdaq Capital Market under symbol SNES with last reported price of $3.40 (June 13, 2025)
- Company will receive proceeds from cash exercises of warrants but not from cashless exercises
- Selling stockholders bear selling expenses while company covers registration costs
SenesTech's business focuses on rodent population control through fertility management products ContraPest and Evolve. The company expects continued operating losses and faces risks including product commercialization challenges, market acceptance, and maintaining Nasdaq listing compliance. Forward-looking statements indicate plans for international expansion and using warrant proceeds for R&D, working capital, and potential strategic acquisitions.
The SEC has declared SenesTech's Form S-3 registration statement effective as of June 24, 2025, at 4:00 P.M. The registration statement was filed under file number 333-288097.
Form S-3 is a simplified security registration form used by companies that have already met certain reporting requirements. This effectiveness notice indicates that SenesTech can now proceed with their intended securities offering as outlined in the registration statement.
This development is significant for investors as it means:
- SenesTech can now legally begin selling the registered securities to the public
- The company has satisfied SEC review requirements
- The registration statement contains complete and accurate information according to SEC standards
The Securities and Exchange Commission has declared SenesTech's Form S-3 registration statement effective as of June 24, 2025, at 5:00 P.M. The registration statement was filed under file number 333-286955.
Form S-3 is a simplified security registration form used by companies that have already met specific reporting requirements. This effectiveness notice indicates that SenesTech can now proceed with their planned securities offering as outlined in the registration statement.
This is a significant development for SenesTech (SNES) as it:
- Allows the company to access the public markets for capital raising
- Provides flexibility to issue various types of securities
- Enables shelf offerings for up to three years from the effective date